Fox Space source of local, national and world news
Sustained global demand for glucagon-like peptide-1 receptor agonists continues to outpace pharmaceutical manufacturing capacity, with active pharmaceutical ingredient synthesis serving as the primary bottleneck.
Contract Manufacturing Allocations
Major drugmakers are deploying multi-billion-dollar capital investments to acquire dedicated contract manufacturing capacity. However, facility validation timelines indicate tight market conditions will persist through mid-2026.
Thousands of apps, a small number with real trials behind them. The distinction is not visible in the…
Widespread adoption of GLP-1 weight-loss drugs is altering pharmaceutical expenditure priorities and consumer food purchasing patterns.
Surging demand for metabolic treatments is redirecting R&D expenditures away from traditional cardiovascular research.
Extreme consumer demand for obesity treatments has strained specialized fill-finish manufacturing and sterile cold-chain distribution.
Continuous monitoring data from wearable devices is gaining formal acceptance as secondary endpoints in clinical drug studies.
Healthcare networks implementing continuous biometric monitoring report lower 30-day readmissions for chronic cardiorespiratory conditions.